Your browser is no longer supported. Please, upgrade your browser.
Settings
PLRX [NASD]
Pliant Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.28 Insider Own1.10% Shs Outstand35.75M Perf Week-2.40%
Market Cap601.54M Forward P/E- EPS next Y-3.22 Insider Trans-4.79% Shs Float32.52M Perf Month-8.32%
Income-81.20M PEG- EPS next Q-0.70 Inst Own85.90% Short Float5.71% Perf Quarter-33.44%
Sales13.20M P/S45.57 EPS this Y-870.70% Inst Trans0.01% Short Ratio15.75 Perf Half Y-50.51%
Book/sh6.83 P/B2.44 EPS next Y-21.20% ROA-28.50% Target Price51.33 Perf Year-26.76%
Cash/sh6.75 P/C2.47 EPS next 5Y- ROE-29.80% 52W Range16.08 - 43.92 Perf YTD-26.76%
Dividend- P/FCF- EPS past 5Y- ROI-14.70% 52W High-62.11% Beta-
Dividend %- Quick Ratio22.90 Sales past 5Y- Gross Margin- 52W Low3.48% ATR0.88
Employees78 Current Ratio22.90 Sales Q/Q-50.00% Oper. Margin- RSI (14)38.92 Volatility4.53% 5.28%
OptionableYes Debt/Eq0.00 EPS Q/Q-28.50% Profit Margin- Rel Volume0.35 Prev Close16.81
ShortableYes LT Debt/Eq0.00 EarningsAug 09 AMC Payout- Avg Volume118.00K Price16.64
Recom1.70 SMA20-4.56% SMA50-7.83% SMA200-39.12% Volume41,159 Change-1.01%
Apr-20-21Initiated BTIG Research Buy $51
Apr-05-21Initiated Citigroup Buy $52
Jun-29-20Initiated Piper Sandler Overweight $50
Jun-29-20Initiated Needham Buy $40
Jun-29-20Initiated Cowen Outperform
Jun-29-20Initiated Citigroup Buy $40
Oct-07-21 08:06AM  
Sep-07-21 12:12PM  
12:07PM  
07:21AM  
07:00AM  
Sep-03-21 04:10PM  
Sep-02-21 08:00AM  
Aug-11-21 06:44AM  
Aug-09-21 04:05PM  
Aug-03-21 08:00AM  
May-13-21 02:30AM  
May-10-21 04:21PM  
May-05-21 08:05AM  
Apr-05-21 08:00AM  
Mar-22-21 08:54AM  
Mar-16-21 04:05PM  
08:00AM  
Feb-18-21 08:30AM  
Feb-17-21 09:00AM  
Feb-09-21 08:52AM  
07:45AM  
Jan-12-21 08:00AM  
Jan-04-21 08:00AM  
Dec-11-20 12:54PM  
Dec-02-20 03:28AM  
Nov-19-20 08:00AM  
Nov-10-20 04:05PM  
Nov-09-20 08:00AM  
Oct-05-20 08:00AM  
Sep-24-20 08:00AM  
Sep-04-20 08:00AM  
Sep-03-20 12:28PM  
Aug-27-20 06:00AM  
Aug-11-20 04:05PM  
Jun-13-20 07:01AM  
Jun-05-20 04:05PM  
Jun-04-20 08:13AM  
Jun-03-20 03:54PM  
11:40AM  
07:35AM  
Jun-02-20 09:56PM  
03:46PM  
06:53AM  
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of av6 and av1 integrins, which is in Phase II single ascending dose/multiple ascending dose trails and completed Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, a small-molecule selective inhibitor of av1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cummings Keith LamontChief Financial OfficerSep 03Option Exercise2.0820,00041,60067,621Sep 03 06:27 PM
Lefebvre EricChief Medical OfficerJun 18Sale28.8712,500360,821137,080Jun 22 07:52 PM
Coulie BernardPresident and CEOJun 14Sale33.034,000132,102449,317Jun 15 08:03 PM
Hull HansChief Business OfficerMay 26Option Exercise2.084,5009,360125,246May 28 07:58 PM
Coulie BernardPresident and CEOMay 14Sale28.643,500100,224453,317May 17 07:34 PM
Coulie BernardPresident and CEOApr 14Sale30.333,500106,161456,817Apr 15 08:05 PM
Coulie BernardPresident and CEOApr 13Option Exercise2.086,00012,48054,840Apr 15 08:05 PM
Lefebvre EricChief Medical OfficerMar 18Sale39.4112,500492,678149,580Mar 19 07:09 PM
Coulie BernardPresident and CEOMar 15Sale38.523,500134,835460,317Mar 17 07:36 PM
Cummings Keith LamontChief Financial OfficerMar 05Option Exercise2.0820,00041,60047,621Mar 05 08:51 PM
Coulie BernardPresident and CEOFeb 16Sale32.673,500114,352463,817Feb 17 07:00 PM
Coulie BernardPresident and CEOJan 14Sale26.383,50092,325467,317Jan 15 07:00 PM
Hull HansChief Business OfficerDec 30Option Exercise2.083,5007,280120,746Jan 04 08:00 PM
Cummings Keith LamontChief Financial OfficerDec 21Option Exercise2.084,5009,36027,621Dec 23 08:00 PM
Lefebvre EricChief Medical OfficerDec 18Sale26.5412,500331,752162,080Dec 21 08:00 PM
Coulie BernardPresident and CEODec 14Sale27.373,50095,790470,817Dec 16 08:00 PM
Cummings Keith LamontChief Financial OfficerDec 01Option Exercise3.6618,73468,53941,855Dec 02 08:00 PM
Cummings Keith LamontChief Financial OfficerDec 01Sale30.0018,734562,03524Dec 02 08:00 PM